{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:32:25Z","timestamp":1780605145326,"version":"3.54.1"},"reference-count":106,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.jacl.2016.04.009","type":"journal-article","created":{"date-parts":[[2016,5,5]],"date-time":"2016-05-05T20:23:25Z","timestamp":1462479805000},"page":"970-986","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Familial hypercholesterolemia\/autosomal dominant hypercholesterolemia: Molecular defects, the LDL-C continuum, and gradients of phenotypic severity"],"prefix":"10.1016","volume":"10","author":[{"given":"JoAnne M.","family":"Foody","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghu","family":"Vishwanath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jacl.2016.04.009_bib1","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1172\/JCI200318925","article-title":"Monogenic hypercholesterolemia: new insights in pathogenesis and treatment","volume":"111","author":"Rader","year":"2003","journal-title":"J Clin Invest"},{"issue":"23","key":"10.1016\/j.jacl.2016.04.009_bib2","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacl.2016.04.009_bib3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.atherosclerosis.2015.09.029","article-title":"Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes","volume":"243","author":"Thompson","year":"2015","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.jacl.2016.04.009_bib4","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","article-title":"Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome","volume":"36","author":"Sjouke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2016.04.009_bib5","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/aje\/kwh236","article-title":"Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review","volume":"160","author":"Austin","year":"2004","journal-title":"Am J Epidemiol"},{"issue":"11","key":"10.1016\/j.jacl.2016.04.009_bib6","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1161\/CIRCULATIONAHA.115.018791","article-title":"Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES)","volume":"133","author":"de Ferranti","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2016.04.009_bib7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCGENETICS.116.001381","article-title":"Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH Registry","volume":"9","author":"deGoma","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jacl.2016.04.009_bib8","series-title":"Praluent (alirocumab) [package insert]","year":"2015"},{"key":"10.1016\/j.jacl.2016.04.009_bib9","series-title":"Lipitor (atorvastatin calcium) [package insert]","year":"2015"},{"key":"10.1016\/j.jacl.2016.04.009_bib10","series-title":"Zetia (ezetimibe) [package insert]","year":"2013"},{"key":"10.1016\/j.jacl.2016.04.009_bib11","series-title":"Repatha (evolocumab) [package insert]","year":"2015"},{"issue":"9965","key":"10.1016\/j.jacl.2016.04.009_bib12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2016.04.009_bib13","series-title":"Juxtapid (lomitapide) [package insert]","year":"2014"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.009_bib14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"issue":"9860","key":"10.1016\/j.jacl.2016.04.009_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2016.04.009_bib16","series-title":"Kynamro (mipomersen sodium) [package insert]","year":"2015"},{"issue":"9719","key":"10.1016\/j.jacl.2016.04.009_bib17","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jacl.2016.04.009_bib18","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","article-title":"Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease","volume":"126","author":"Stein","year":"2012","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacl.2016.04.009_bib19","doi-asserted-by":"crossref","first-page":"e49006","DOI":"10.1371\/journal.pone.0049006","article-title":"Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy","volume":"7","author":"McGowan","year":"2012","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.jacl.2016.04.009_bib20","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2016.04.009_bib21","series-title":"Crestor (rosuvastatin calcium) [package insert]","year":"2015"},{"key":"10.1016\/j.jacl.2016.04.009_bib22","series-title":"Zocor (simvastatin) [package insert]","year":"2015"},{"issue":"1","key":"10.1016\/j.jacl.2016.04.009_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jacl.2013.09.004","article-title":"JCL roundtable: drug treatment of severe forms of familial hypercholesterolemia","volume":"8","author":"Brown","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2016.04.009_bib24","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jacl.2014.09.005","article-title":"The doctor's dilemma: challenges in the diagnosis and care of homozygous familial hypercholesterolemia","volume":"8","author":"Baum","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2016.04.009_bib25","series-title":"The Metabolic & Molecular Bases of Inherited Disease","first-page":"2863","article-title":"Familial hypercholesterolemia","author":"Goldstein","year":"2001"},{"key":"10.1016\/j.jacl.2016.04.009_bib26","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2016.04.009_bib27","unstructured":"National Institute for Health and Care Excellence (NICE). Familial Hypercholesterolemia: Identification and Management. Clinical Guideline. Published August 27, 2008. Available at: https:\/\/www.nice.org.uk\/guidance\/cg71\/resources\/familial-hypercholesterolaemia-identification-and-management-975623384005. Accessed January 30,\u00a02016."},{"issue":"45","key":"10.1016\/j.jacl.2016.04.009_bib28","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacl.2016.04.009_bib29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2013.11.025","article-title":"Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation","volume":"171","author":"Watts","year":"2014","journal-title":"Int J Cardiol"},{"issue":"3 Suppl","key":"10.1016\/j.jacl.2016.04.009_bib30","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2011.04.003","article-title":"Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Goldberg","year":"2011","journal-title":"J Clin Lipidol"},{"issue":"9874","key":"10.1016\/j.jacl.2016.04.009_bib31","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(12)62127-8","article-title":"Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study","volume":"381","author":"Talmud","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jacl.2016.04.009_bib32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/CIRCGENETICS.112.965137","article-title":"When it looks like familial hypercholesterolemia\u2026but is not","volume":"5","author":"Fazio","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"issue":"11","key":"10.1016\/j.jacl.2016.04.009_bib33","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1161\/CIRCULATIONAHA.110.979450","article-title":"Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children","volume":"123","author":"van der Graaf","year":"2011","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacl.2016.04.009_bib34","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ejhg.2010.94","article-title":"A fourth locus for autosomal dominant hypercholesterolemia maps at 16q22.1","volume":"18","author":"Marques-Pinheiro","year":"2010","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"10.1016\/j.jacl.2016.04.009_bib35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/humu.22215","article-title":"Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation","volume":"34","author":"Marduel","year":"2013","journal-title":"Hum Mutat"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.009_bib36","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2013.09.007","article-title":"APOE p.Leu167del mutation in familial hypercholesterolemia","volume":"231","author":"Awan","year":"2013","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.jacl.2016.04.009_bib37","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/CIRCRESAHA.115.304660","article-title":"Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia","volume":"115","author":"Fouchier","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.jacl.2016.04.009_bib38","first-page":"53","article-title":"The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations","volume":"3","author":"Castro-Or\u00f3s","year":"2010","journal-title":"Appl Clin Genet"},{"issue":"5","key":"10.1016\/j.jacl.2016.04.009_bib39","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1399-0004.2010.01485.x","article-title":"A presumptive new locus for autosomal dominant hypercholesterolemia mapping to 8q24.22","volume":"79","author":"Cenarro","year":"2011","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacl.2016.04.009_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00330-1","article-title":"A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia","volume":"168","author":"Marks","year":"2003","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.jacl.2016.04.009_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5551\/jat.27227","article-title":"Autosomal recessive hypercholesterolemia: a mild phenotype of familial hypercholesterolemia: insight from the kinetic study using stable isotope and animal studies","volume":"22","author":"Tada","year":"2015","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.009_bib42","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.atherosclerosis.2011.08.004","article-title":"A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene","volume":"219","author":"Tada","year":"2011","journal-title":"Atherosclerosis"},{"issue":"5520","key":"10.1016\/j.jacl.2016.04.009_bib43","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1126\/science.1060458","article-title":"Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein","volume":"292","author":"Garcia","year":"2001","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.009_bib44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00041433-200304000-00002","article-title":"Molecular mechanisms of autosomal recessive hypercholesterolemia","volume":"14","author":"Cohen","year":"2003","journal-title":"Curr Opin Lipidol"},{"issue":"3","key":"10.1016\/j.jacl.2016.04.009_bib45","first-page":"129","article-title":"Hypercholesterolaemia and hepatosplenomegaly: two manifestations of cholesteryl ester storage disease","volume":"73","author":"Sjouke","year":"2015","journal-title":"Neth J Med"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.009_bib46","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.atherosclerosis.2010.11.005","article-title":"Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan","volume":"214","author":"Mabuchi","year":"2011","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.jacl.2016.04.009_bib47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/jmedgenet-2014-102405","article-title":"Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR\/APOB\/PCSK9 mutations","volume":"51","author":"Futema","year":"2014","journal-title":"J Med Genet"},{"issue":"3 Suppl","key":"10.1016\/j.jacl.2016.04.009_bib48","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2013.03.005","article-title":"Emerging LDL therapies: Using human genetics to discover new therapeutic targets for plasma lipids","volume":"7","author":"Cohen","year":"2013","journal-title":"J Clin Lipidol"},{"issue":"11","key":"10.1016\/j.jacl.2016.04.009_bib49","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels","volume":"45","author":"Willer","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.jacl.2016.04.009_bib50","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.atherosclerosis.2014.06.005","article-title":"Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin\/kexin type 9 (PCSK9) gain-of-function mutation","volume":"236","author":"Mabuchi","year":"2014","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.jacl.2016.04.009_bib51","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1469-1809.2012.00724.x","article-title":"Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment","volume":"76","author":"Usifo","year":"2012","journal-title":"Ann Hum Genet"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.009_bib52","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","article-title":"Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment","volume":"223","author":"Raal","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2016.04.009_bib53","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2147\/TACG.S44315","article-title":"The genetics of familial hypercholesterolemia and emerging therapies","volume":"8","author":"Vogt","year":"2015","journal-title":"Appl Clin Genet"},{"issue":"12","key":"10.1016\/j.jacl.2016.04.009_bib54","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0002-9149(98)00692-4","article-title":"Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group","volume":"82","author":"Mabuchi","year":"1998","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.009_bib55","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0021-9150(99)00435-9","article-title":"Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia","volume":"150","author":"Raal","year":"2000","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.009_bib56","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0021-9150(00)00675-4","article-title":"Therapy with statins is effective in some patients with homozygous familial hypercholesterolemia","volume":"153","author":"Tsimihodimos","year":"2000","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.jacl.2016.04.009_bib57","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0022-3476(05)81956-0","article-title":"Treatment of children with homozygous familial hypercholesterolemia: safety and efficacy of low-density lipoprotein apheresis","volume":"120","author":"Uauy","year":"1992","journal-title":"J\u00a0Pediatr"},{"issue":"1","key":"10.1016\/j.jacl.2016.04.009_bib58","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2009.11.018","article-title":"The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation","volume":"210","author":"Noguchi","year":"2010","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.009_bib59","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2796.1999.00518.x","article-title":"Familial defective apolipoprotein B-100 homozygote with premature coronary atherosclerosis. A case report","volume":"246","author":"Horinek","year":"1999","journal-title":"J Intern Med"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.009_bib60","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0021-9150(94)05528-Q","article-title":"The affinity of low-density lipoproteins and of very-low-density lipoprotein remnants for the low-density lipoprotein receptor in homozygous familial defective apolipoprotein B-100","volume":"115","author":"Gallagher","year":"1995","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.jacl.2016.04.009_bib61","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1172\/JCI116915","article-title":"Accumulation of \u201csmall dense\u201d low density lipoproteins (LDL) in a homozygous patients with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor","volume":"92","author":"M\u00e4rz","year":"1993","journal-title":"J Clin Invest"},{"issue":"Suppl I","key":"10.1016\/j.jacl.2016.04.009_bib62","first-page":"691","article-title":"Homozygosity for familial defective apolipoprotein B-100 (FDB) is associated with lower plasma cholesterol concentrations than homozygosity for familial hypercholesterolemia (FH)","volume":"86","author":"Funke","year":"1992","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.009_bib63","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.atherosclerosis.2005.08.015","article-title":"Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia","volume":"186","author":"Pisciotta","year":"2006","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.jacl.2016.04.009_bib64","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.atherosclerosis.2004.01.020","article-title":"Autosomal recessive hypercholesterolaemia: long-term follow up and response to treatment","volume":"174","author":"Naoumova","year":"2004","journal-title":"Atherosclerosis"},{"issue":"9309","key":"10.1016\/j.jacl.2016.04.009_bib65","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0140-6736(02)07955-2","article-title":"Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis","volume":"359","author":"Arca","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.009_bib66","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.atherosclerosis.2005.11.016","article-title":"Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison","volume":"188","author":"Pisciotta","year":"2006","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.jacl.2016.04.009_bib67","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1161\/01.ATV.13.7.1076","article-title":"Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100","volume":"13","author":"Rubinsztein","year":"1993","journal-title":"Arterioscler Thromb"},{"issue":"3","key":"10.1016\/j.jacl.2016.04.009_bib68","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1093\/clinchem\/47.3.438","article-title":"Compound heterozygous familial hypercholesterolemia and familial defective apolipoprotein B-100 produce exaggerated hypercholesterolemia","volume":"47","author":"Tai","year":"2001","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.jacl.2016.04.009_bib69","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/(SICI)1098-1004(1996)7:4<340::AID-HUMU8>3.0.CO;2-C","article-title":"Phenotypic expression in double heterozygotes for familial hypercholesterolemia and familial defective apolipoprotein B-100","volume":"7","author":"Benlian","year":"1996","journal-title":"Hum Mutat"},{"issue":"7","key":"10.1016\/j.jacl.2016.04.009_bib70","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF01644767","article-title":"Identification of a heterozygous compound individual with familial hypercholesterolemia and familial defective apolipoprotein B-100","volume":"69","author":"Rauh","year":"1991","journal-title":"Klin Wochenschr"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.009_bib71","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11748-008-0335-7","article-title":"Triple coronary artery bypass graft in a 10-year-old child with familial hypercholesterolemia","volume":"57","author":"Nemati","year":"2009","journal-title":"Gen Thorac Cardiovasc Surg"},{"issue":"1","key":"10.1016\/j.jacl.2016.04.009_bib72","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpeds.2010.06.027","article-title":"Sudden death in a 4-year-old boy: a near-complete occlusion of the coronary artery caused by an aggressive low-density lipoprotein receptor mutation (W556R) in homozygous familial hypercholesterolemia","volume":"158","author":"Widhalm","year":"2011","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.jacl.2016.04.009_bib73","first-page":"363","article-title":"Bilateral carotid atherosclerosis: an inevitable consequence of homozygous familial hypercholesterolemia","volume":"20","author":"Nemati","year":"2011","journal-title":"Heart Valve Dis"},{"issue":"4","key":"10.1016\/j.jacl.2016.04.009_bib74","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.1526-0968.2003.00075.x","article-title":"Hypercholesterolemic valvulopathy: an aspect of malignant atherosclerosis","volume":"7","author":"Kawaguchi","year":"2003","journal-title":"Ther Apher Dial"},{"issue":"279","key":"10.1016\/j.jacl.2016.04.009_bib75","first-page":"731","article-title":"Natural history and cardiac manifestations of homozygous familial hypercholesterolaemia","volume":"76","author":"Haitas","year":"1990","journal-title":"Quart J Med"},{"issue":"4","key":"10.1016\/j.jacl.2016.04.009_bib76","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1161\/ATVBAHA.107.160408","article-title":"Vascular calcifications in homozygote familial hypercholesterolemia","volume":"28","author":"Awan","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"11","key":"10.1016\/j.jacl.2016.04.009_bib77","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1161\/01.ATV.0000094410.66558.9A","article-title":"Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia","volume":"23","author":"Soutar","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"Suppl","key":"10.1016\/j.jacl.2016.04.009_bib78","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J Lipid Res"},{"issue":"6","key":"10.1016\/j.jacl.2016.04.009_bib79","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/hrt.80.6.583","article-title":"Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia","volume":"80","author":"Rallidis","year":"1998","journal-title":"Heart"},{"issue":"1","key":"10.1016\/j.jacl.2016.04.009_bib80","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jacl.2013.11.002","article-title":"Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy","volume":"8","author":"Vishwanath","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2016.04.009_bib81","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","article-title":"Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands","volume":"209","author":"Pijlman","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2016.04.009_bib82","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.fob.2014.03.007","article-title":"Mutation G805R in the transmembrane domain of the LDL receptor gene causes familial hypercholesterolemia by inducing ectodomain cleavage of the LDL receptor in the endoplasmic reticulum","volume":"4","author":"Str\u00f8m","year":"2014","journal-title":"FEBS Open Bio"},{"issue":"15","key":"10.1016\/j.jacl.2016.04.009_bib83","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.2217\/pgs.15.113","article-title":"Type of LDLR mutation and the pharmacogenetics of familial hypercholesterolemia treatment","volume":"16","author":"Santos","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.jacl.2016.04.009_bib84","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0021-9150(96)06007-8","article-title":"Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects","volume":"129","author":"Raal","year":"1997","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.009_bib85","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1517\/13543784.2011.547471","article-title":"Mipomersen, an antisense apolipoprotein B synthesis inhibitor","volume":"20","author":"Bell","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jacl.2016.04.009_bib86","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosissup.2015.02.002","article-title":"Managing homozygous familial hypercholesterolaemia from cradle to grave","volume":"18","author":"Thompson","year":"2015","journal-title":"Atheroscler Suppl"},{"issue":"5","key":"10.1016\/j.jacl.2016.04.009_bib87","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1194\/jlr.M300448-JLR200","article-title":"Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation","volume":"45","author":"Tremblay","year":"2004","journal-title":"J Lipid Res"},{"issue":"5","key":"10.1016\/j.jacl.2016.04.009_bib88","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1042\/CS20090402","article-title":"Regulation of plasma LDL: the apoB paradigm","volume":"118","author":"Sniderman","year":"2009","journal-title":"Clin Sci (lond)"},{"issue":"8","key":"10.1016\/j.jacl.2016.04.009_bib89","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.ATV.0000133684.77013.88","article-title":"Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9","volume":"24","author":"Ouguerram","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.009_bib90","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0022-2275(20)33899-2","article-title":"VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100","volume":"39","author":"Zulewski","year":"1998","journal-title":"J Lipid Res"},{"issue":"19","key":"10.1016\/j.jacl.2016.04.009_bib91","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2014.01.060","article-title":"The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies","volume":"63","author":"Sniderman","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2016.04.009_bib92","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/CRD.0000000000000014","article-title":"Antihyperlipidemic therapies targeting PCSK9","volume":"22","author":"Weinreich","year":"2014","journal-title":"Cardiol Rev"},{"issue":"6","key":"10.1016\/j.jacl.2016.04.009_bib93","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.100.6.594","article-title":"Stimulation of fecal steroid excretion after infusion of recombinant proapolipo-protein\u00a0A-I. Potential reverse cholesterol transport in humans","volume":"100","author":"Eriksson","year":"1999","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jacl.2016.04.009_bib94","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/ATVBAHA.113.301981","article-title":"Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux","volume":"33","author":"Diditchenko","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.jacl.2016.04.009_bib95","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jcph.194","article-title":"A multiple ascending dose study of CSL112, an infused formulation of ApoA-I","volume":"54","author":"Easton","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"46","key":"10.1016\/j.jacl.2016.04.009_bib96","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","article-title":"Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial","volume":"35","author":"Tardif","year":"2014","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.jacl.2016.04.009_bib97","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/nm1195-1148","article-title":"A pilot study of ex\u00a0vivo gene therapy for homozygous familial hypercholesterolaemia","volume":"1","author":"Grossman","year":"1995","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.jacl.2016.04.009_bib98","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.2174\/138161211797247550","article-title":"Gene therapy for familial hypercholesterolemia","volume":"17","author":"Van Craeyveld","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacl.2016.04.009_bib99","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1755-7682-3-36","article-title":"LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives","volume":"3","author":"Al-Allaf","year":"2010","journal-title":"Int Arch Med"},{"issue":"20","key":"10.1016\/j.jacl.2016.04.009_bib100","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","author":"Raal","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.009_bib101","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosissup.2014.07.005","article-title":"Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia","volume":"15","author":"Cuchel","year":"2014","journal-title":"Atheroscler Suppl"},{"issue":"5","key":"10.1016\/j.jacl.2016.04.009_bib102","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1161\/01.ATV.21.5.832","article-title":"Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia","volume":"21","author":"O'Neill","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.jacl.2016.04.009_bib103","doi-asserted-by":"crossref","first-page":"e16721","DOI":"10.1371\/journal.pone.0016721","article-title":"Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB-100 are not being adequately treated","volume":"6","author":"Leren","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jacl.2016.04.009_bib104","doi-asserted-by":"crossref","first-page":"323","DOI":"10.5551\/jat.13.323","article-title":"Cholesterol-years score is associated with development of senile degenerative aortic stenosis in heterozygous familial hypercholesterolemia","volume":"13","author":"Nozue","year":"2006","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"10.1016\/j.jacl.2016.04.009_bib105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00043798-199602000-00009","article-title":"The extracranial carotid artery in familial hypercholesterolaemia: relationship of intimal-medial thickness and plaque morphology with plasma lipids and coronary heart disease","volume":"3","author":"Sidhu","year":"1996","journal-title":"J Cardiovasc Risk"},{"issue":"12","key":"10.1016\/j.jacl.2016.04.009_bib106","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1046\/j.1365-2362.1998.00399.x","article-title":"Carotid intima-media thickness and plaque in patients with familial hypercholesterolaemia mutations and control subjects","volume":"28","author":"Tonstad","year":"1998","journal-title":"Eur J Clin Invest"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287416301891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287416301891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T02:21:00Z","timestamp":1655691660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287416301891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":106,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S1933287416301891"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2016.04.009","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Familial hypercholesterolemia\/autosomal dominant hypercholesterolemia: Molecular defects, the LDL-C continuum, and gradients of phenotypic severity","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2016.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}